关键词：癌症；没有节制；鳞状；细胞（表皮）癌，腺癌；大细胞（未分化）癌
摘 要：Cancer occurs when, after undergoing cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Non-small cell lung cancer is the commonest type of lung cancer. It grows and spreads quite slowly. Smoking is considered as a major cause of lung cancer, though lung cancer also occurs in non-smokers. Non-small cell lung cancer is of three types: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Some of the common symptoms associated with non-small cell lung cancer are chest pain, a cough that does not go away, coughing up blood, fatigue, loss of appetite, losing weight without trying, shortness of breath, and wheezing.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Product Profiles

04.1.1 Iressa

04.1.2 Abraxane

04.1.3 Alimta

04.1.4 Gemzar

04.1.5 Xalkori

04.1.6 Avastin

04.1.7 Tarceva

05. Market Research Methodology

05.1 Market Research Process

05.2 Research Methodology

06. Introduction

07. Market Landscape

07.1 Market Overview

07.2 Market Size and Forecast

07.3 Five Forces Analysis

08. Market Segmentation by Molecule Type

08.1 Biologics

08.2 Small Molecules

09. Market Segmentation by Route of

Administration

09.1 Oral

09.2 Parenteral

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Market Share Analysis 2013

18.3 AstraZeneca

18.3.1 Iressa

18.4 Celgene

18.4.1 Abraxane

18.5 Eli Lilly

18.5.1 Alimta

18.5.2 Gemzar

18.6 F. Hoffmann-La Roche

18.6.1 Avastin

18.6.2 Tarceva

18.7 Pfizer

18.7.1 Xalkori

18.8 Other Prominent Vendors

19. Pipeline Portfolio

20. Key Vendor Analysis

20.1 AstraZeneca

20.1.1 Key Facts

20.1.2 Business Overview

20.1.3 Business Segmentation

20.1.4 Business Strategy

20.1.5 Business Segmentation by Revenue

20.1.6 Sales by Geography

20.1.7 Key Information

20.1.8 SWOT Analysis

20.2 Celgene

20.2.1 Key Facts

20.2.2 Business Overview

20.2.3 Business Strategy

20.2.4 Business Segmentation by Revenue

20.2.5 Sales by Geography

20.2.6 Key Information

20.2.7 SWOT Analysis

20.3 Eli Lilly

20.3.1 Key Facts

20.3.2 Business Overview

20.3.3 Business Segmentation by Revenue

20.3.4 Sales by Geography

20.3.5 Business Strategy

20.3.6 Key Information

20.3.7 SWOT Analysis

20.4 F. Hoffmann-La Roche

20.4.1 Key Facts

20.4.2 Business Overview

20.4.3 Business Segmentation by Revenue

20.4.4 Sales by Geography

20.4.5 Business Strategy

20.4.6 Key Information

20.4.7 SWOT Analysis

20.5 Pfizer

20.5.1 Key Facts

20.5.2 Business Overview

20.5.3 Business Segmentation

20.5.4 Business Segmentation by Revenue

20.5.5 Business Segmentation by Revenue 2012 and 2013

20.5.6 Sales by Geography

20.5.7 Business Strategy

20.5.8 Key Information

20.5.9 SWOT Analysis

21. Other Reports in this Series